loading
前日終値:
$4.33
開ける:
$4.35
24時間の取引高:
1.07M
Relative Volume:
1.05
時価総額:
$87.42M
収益:
$1.54M
当期純損益:
$-84.53M
株価収益率:
-0.7774
EPS:
-5.8145
ネットキャッシュフロー:
$-73.65M
1週間 パフォーマンス:
-15.99%
1か月 パフォーマンス:
-37.74%
6か月 パフォーマンス:
-55.42%
1年 パフォーマンス:
-76.27%
1日の値動き範囲:
Value
$4.2201
$4.72
1週間の範囲:
Value
$4.2201
$5.4025
52週間の値動き範囲:
Value
$4.2201
$20.56

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Name
名前
Corbus Pharmaceuticals Holdings Inc
Name
セクター
Healthcare (1052)
Name
電話
617-963-0103
Name
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Name
職員
36
Name
Twitter
@corbuspharma
Name
次回の収益日
2026-11-11
Name
最新のSEC提出書
Name
CRBP's Discussions on Twitter

Compare CRBP vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CRBP icon
CRBP
Corbus Pharmaceuticals Holdings Inc
4.52 87.42M 1.54M -84.53M -73.65M -5.8145
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-29 開始されました Guggenheim Buy
2025-07-30 再開されました B. Riley Securities Buy
2025-02-28 開始されました William Blair Outperform
2024-12-02 開始されました Piper Sandler Overweight
2024-07-30 開始されました Wedbush Outperform
2024-07-22 再開されました H.C. Wainwright Buy
2024-06-26 開始されました B. Riley Securities Buy
2024-06-03 繰り返されました Oppenheimer Outperform
2024-05-13 開始されました RBC Capital Mkts Outperform
2024-03-06 アップグレード Jefferies Hold → Buy
2020-09-08 ダウングレード BTIG Research Buy → Neutral
2020-09-08 ダウングレード Jefferies Buy → Hold
2020-09-08 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-09-08 ダウングレード ROTH Capital Buy → Neutral
2020-07-07 開始されました ROTH Capital Buy
2020-06-17 開始されました BTIG Research Buy
2020-03-26 開始されました Nomura Buy
2019-04-05 開始されました Jefferies Buy
2019-03-20 開始されました Oppenheimer Outperform
2019-01-11 繰り返されました Cantor Fitzgerald Overweight
2018-12-26 開始されました H.C. Wainwright Buy
2018-12-07 開始されました RBC Capital Mkts Outperform
2018-10-24 開始されました B. Riley FBR Buy
2018-01-19 開始されました Raymond James Outperform
2017-12-14 繰り返されました Cantor Fitzgerald Overweight
2017-11-08 繰り返されました Noble Financial Buy
2017-09-29 再開されました Noble Financial Buy
2017-03-30 繰り返されました Cantor Fitzgerald Overweight
2016-11-15 繰り返されました JMP Securities Mkt Outperform
2016-11-11 繰り返されました Noble Financial Buy
すべてを表示

Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース

pulisher
Oct 10, 2026

Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38 - Simply Wall Street

Oct 10, 2026
pulisher
Oct 09, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2026
pulisher
Oct 08, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 08, 2026
pulisher
Oct 07, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 07, 2026
pulisher
Oct 06, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 06, 2026
pulisher
Oct 05, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Oct 05, 2026
pulisher
Oct 05, 2026

(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Oct 05, 2026
pulisher
Oct 02, 2026

RA Capital Management Acquires 1,914,788 Shares of Corbus Pharmaceuticals (CRBP) - GuruFocus

Oct 02, 2026
pulisher
Oct 02, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 02, 2026
pulisher
Oct 01, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 01, 2026
pulisher
Sep 30, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 30, 2026
pulisher
Sep 30, 2026

Four parties report the same Corbus (CRBP) stake, held directly by one fund. - stocktitan.net

Sep 30, 2026
pulisher
Sep 29, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 29, 2026
pulisher
Sep 29, 2026

EBITDA of Corbus Pharmaceuticals Holdings Inc – HAN:3371 - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - finance.yahoo.com

Sep 29, 2026
pulisher
Sep 29, 2026

About 14,000 U.S. patients may qualify yearly for another throat cancer treatment. Corbus doses its first trial patient. - Stock Titan

Sep 29, 2026
pulisher
Sep 28, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Sep 28, 2026
pulisher
Sep 28, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Sep 28, 2026
pulisher
Sep 28, 2026

Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - Kalkine Media

Sep 28, 2026
pulisher
Sep 25, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 25, 2026
pulisher
Sep 25, 2026

Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - Kalkine Media

Sep 25, 2026
pulisher
Sep 25, 2026

(CRBP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Sep 25, 2026
pulisher
Sep 24, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Sep 24, 2026
pulisher
Sep 24, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Sep 24, 2026
pulisher
Sep 24, 2026

What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media

Sep 24, 2026
pulisher
Sep 23, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Sep 23, 2026
pulisher
Sep 23, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Sep 23, 2026
pulisher
Sep 22, 2026

Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 22, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 22, 2026
pulisher
Sep 22, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 22, 2026
pulisher
Sep 21, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 21, 2026
pulisher
Sep 21, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 21, 2026
pulisher
Sep 21, 2026

Corbus Pharmaceuticals Holdings (Nasdaq:CRBP)Stock Analysis - Simply Wall Street

Sep 21, 2026
pulisher
Sep 18, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 18, 2026
pulisher
Sep 18, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 18, 2026
pulisher
Sep 18, 2026

CRBP - Finviz

Sep 18, 2026
pulisher
Sep 17, 2026

Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com

Sep 17, 2026
pulisher
Sep 17, 2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss TherapySlideshow (NASDAQ:CRBP) 2026-09-17 - Seeking Alpha

Sep 17, 2026
pulisher
Sep 16, 2026

Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com

Sep 16, 2026
pulisher
Sep 15, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 15, 2026
pulisher
Sep 14, 2026

Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com

Sep 14, 2026
pulisher
Sep 14, 2026

Corbus Pharmaceuticals Announces Positive Topline Data from - GlobeNewswire

Sep 14, 2026
pulisher
Sep 14, 2026

Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data - finance.yahoo.com

Sep 14, 2026
pulisher
Sep 14, 2026

Corbus Pharmaceuticals Announces Positive Topline Data from - GlobeNewswire

Sep 14, 2026
pulisher
Sep 14, 2026

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - Yahoo Finance

Sep 14, 2026
pulisher
Sep 11, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Sep 11, 2026
pulisher
Sep 11, 2026

Corbus Pharmaceuticals to Host Sept. 14 Webcast on Topline CANYON-1 Phase 1b Data for CRB-913 in Obesity - Quiver Quantitative

Sep 11, 2026
pulisher
Sep 11, 2026

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo! Finance Canada

Sep 11, 2026
pulisher
Sep 11, 2026

Corbus Pharmaceuticals to Host Conference Call to Discuss - GlobeNewswire

Sep 11, 2026
pulisher
Sep 11, 2026

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo Finance

Sep 11, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Corbus Pharmaceuticals Holdings Inc (CRBP) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Saxena Nishant C
Chief Business Officer
Aug 11 '26
Buy
9.63
2,600
25,036
77,900
Stifel, Nicolaus & Company, In
Officer
Aug 07 '26
Proposed Sale
10.08
17,000
171,396
0
Cohen Yuval
Chief Executive Officer
Aug 07 '26
Sale
10.08
17,000
171,396
157,316
Moran Sean F.
Chief Financial Officer
Aug 07 '26
Sale
10.08
12,000
120,971
84,694
Stifel, Nicolaus & Company, In
Officer
Aug 07 '26
Proposed Sale
10.08
12,000
120,971
0
Smethurst Dominic
Officer
Jul 27 '26
Proposed Sale
9.20
23,025
211,818
0
Kung Winston
Director
Jun 10 '26
Sale
7.91
2,026
16,033
12,140
Altmeyer Anne
Director
Jun 10 '26
Sale
7.91
2,412
19,088
7,579
Jenkins John Kenneth
Director
Jun 10 '26
Sale
7.91
4,800
37,986
3,833
Saxena Nishant C
Chief Business Officer
Jun 03 '26
Buy
7.58
9,000
68,220
75,300
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):